AMGN241227P450000
- 0.00
- 0.000.00%
Amgen Newsroom
Is Amgen (NASDAQ:AMGN) a High-Quality Dividend Stock on Sale?
Why the 'Dogs of the Dow' Stocks Just Might Deliver in 2025
Sector Update: Health Care Stocks Advance Late Afternoon
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Spotlight on Amgen: Analyzing the Surge in Options Activity
Lilly, Amgen Sue HHS Over Certification of Drug Discount Program Recipients
Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
What's Going On With Amgen Stock On Friday?
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $350
Goldman Sachs, Salesforce Share Gains Lead Dow's 300-Point Jump
Why Is Novo Nordisk Crashing After Data for Next-gen Weight Loss Drug?
U.S. stock market fluctuations | Amgen once rose over 3%, competing company Novo-Nordisk A/S's weight loss drug trial results fell short of expectations.
On December 20, the stock of Amgen (AMGN.US) rose more than 3% to $269.61 at the beginning of trading. According to reports, Novo-Nordisk A/S announced the main results of a Phase 3 clinical trial named REDEFINE 1 on Friday. When assessing the treatment effect for all patients who adhered to the treatment, those treated with CagriSema experienced a weight loss of 22.7% after 68 weeks, which was lower than the market expectation of 25%. The stock price of Novo-Nordisk A/S plummeted over 20%. (Gelonghui)
Express News | Shares of Viking Therapeutics up 4.2%, Amgen up 1%
Amgen, Eli Lilly, Viking Therapeutics Shares Rise Pre-Bell After Novo Nordisk's Obesity Treatment Falls Short of Expectations
Amgen Shares Are Trading Higher. Weight-loss Related Stocks Are up on Friday Following Weaker-than-expected Data From Competitor Lilly.
The weight loss effect of the new drug was below expectations, and Novo-Nordisk A/S saw its stock plummet by 28% in Pre-Market Trading, while competitor Eli Lilly and Co surged over 12%.
The experimental results show that patients who received subcutaneous injections of CagriSema lost an average of 22.7% of their weight after 68 weeks. If volunteers who dropped out of the trial are included, the average weight loss effect decreases to 20.4%, both below the company's previous expectation of 25%.
Express News | Amgen Shares up 5.3% Premarket After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected
Low-Volatility Funds From Vanguard and Others Sound Ideal for This Market. Why They Might Not Be.
Jefferies Adjusts Amgen Price Target to $350 From $380, Maintains Buy Rating